AU2002220265A1 - Compositions for inhibiting grb7 - Google Patents

Compositions for inhibiting grb7

Info

Publication number
AU2002220265A1
AU2002220265A1 AU2002220265A AU2026502A AU2002220265A1 AU 2002220265 A1 AU2002220265 A1 AU 2002220265A1 AU 2002220265 A AU2002220265 A AU 2002220265A AU 2026502 A AU2026502 A AU 2026502A AU 2002220265 A1 AU2002220265 A1 AU 2002220265A1
Authority
AU
Australia
Prior art keywords
grb7
inhibiting
compositions
inhibiting grb7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220265A
Inventor
David N. Krag
Lyn Oligino
Stephanie C. Pero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont and State Agricultural College
Original Assignee
University of Vermont
University of Vermont and State Agricultural College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Vermont, University of Vermont and State Agricultural College filed Critical University of Vermont
Publication of AU2002220265A1 publication Critical patent/AU2002220265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002220265A 2000-11-03 2001-11-05 Compositions for inhibiting grb7 Abandoned AU2002220265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24575500P 2000-11-03 2000-11-03
US60/245,755 2000-11-03
PCT/US2001/047400 WO2002036142A2 (en) 2000-11-03 2001-11-05 Compositions for inhibiting grb7

Publications (1)

Publication Number Publication Date
AU2002220265A1 true AU2002220265A1 (en) 2002-05-15

Family

ID=22927948

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220265A Abandoned AU2002220265A1 (en) 2000-11-03 2001-11-05 Compositions for inhibiting grb7

Country Status (4)

Country Link
US (1) US7229960B2 (en)
AU (1) AU2002220265A1 (en)
CA (1) CA2427858A1 (en)
WO (1) WO2002036142A2 (en)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688839B2 (en) * 1993-11-30 1998-03-19 Tanox, Inc. Novel apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof
US6300482B1 (en) * 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US20060205020A1 (en) * 1995-09-06 2006-09-14 Icos Corporation Cell-cycle checkpoint genes
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO1998035043A1 (en) * 1997-02-06 1998-08-13 Genetics Institute, Inc. Human sdf-5 protein and compositions
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US20030171542A1 (en) * 1997-07-03 2003-09-11 Zymogenetics, Inc. Mammalian secretory peptide - 9
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
DE60016398T2 (en) * 1999-04-26 2005-12-22 Chugai Seiyaku K.K. tumor suppressor
EP1241255A4 (en) * 1999-12-16 2003-02-26 Chugai Pharmaceutical Co Ltd Novel human rna helicase, helicain
WO2001095205A1 (en) * 1999-12-30 2001-12-13 Jeffrey Alnwick Method and system for ordering items over the internet
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
WO2002064791A2 (en) * 2000-12-08 2002-08-22 Curagen Corporation Proteins and nucleic acids encoding same
US20020164703A1 (en) * 2000-12-21 2002-11-07 Krzysztof Pawlowski Card-domain containing polypeptides, encoding nucleic acids, and methods of use
US7381701B2 (en) * 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL158293A0 (en) * 2001-04-10 2004-05-12 Agensys Inc Nucleic acid and corresponding protein entitled 158p3d2 and pharmaceutical compositions containing the same
EP1252894A1 (en) * 2001-04-26 2002-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
JP2002348254A (en) * 2001-05-24 2002-12-04 Japan Science & Technology Corp Agent for curing neurogenic tumor
US20030109440A1 (en) * 2001-10-03 2003-06-12 Rigel Pharmaceuticals, Incorporated GRB7: novel regulator of lymphocyte signaling
US20050026833A1 (en) * 2001-11-08 2005-02-03 Rabbani Shafaat Ahmed PSP-94: use for treatment of hypercalcemia and bone metastasis
US7422862B2 (en) * 2001-11-28 2008-09-09 The Burnham Institute Methods for identifying modulators of apoptosis
US9575070B2 (en) * 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
US20050089896A1 (en) * 2003-02-18 2005-04-28 Roy Frans V. Method to control tumor progression and invasiveness
US20030186241A1 (en) * 2002-03-20 2003-10-02 Ken-Shwo Dai Human choline/ethanolamine kinase (HCEK)-related gene variant associated with lung cancers
AU2003227861A1 (en) * 2002-04-11 2003-10-27 Oxford Glycosciences (Uk) Ltd Protein involved in cancer
JP2004057003A (en) * 2002-06-03 2004-02-26 Norihiro Chano Rb1 gene-induced protein (rb1cc1) and gene
US20060052582A1 (en) * 2002-06-11 2006-03-09 Joan Roig Amores Identification of inhibitors of mitosis
WO2004005351A2 (en) * 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
US7723018B2 (en) * 2002-08-30 2010-05-25 Rigel Pharmaceuticals, Incorporated Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
SI1546182T1 (en) * 2002-09-11 2011-04-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
DE10248751A1 (en) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslocation molecules and their use
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
CN1209372C (en) * 2002-11-27 2005-07-06 上海市肿瘤研究所 Human tumor relative gene CT120 in human 17p 13.3 area and coding protein thereof
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ATE472338T1 (en) 2003-02-20 2010-07-15 Seattle Genetics Inc ANTI-CD70 ANTIBODY DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
CN100340574C (en) * 2003-02-27 2007-10-03 上海睿星基因技术有限公司 Tumour tag and its use
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005019429A2 (en) * 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
EP1727556A2 (en) * 2004-02-17 2006-12-06 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US8759317B2 (en) 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
US20050271670A1 (en) * 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
KR20070013323A (en) * 2004-05-07 2007-01-30 더 리전츠 오브 더 유니버시티 오브 캘리포니아 Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment
ES2382661T3 (en) * 2004-06-04 2012-06-12 The Scripps Research Institute Compositions and procedures for the treatment of neovascular diseases
WO2006028393A1 (en) * 2004-09-09 2006-03-16 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disease
WO2006050373A2 (en) * 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene protein encoded therein expression vector containing same and cell transformed by said vector
JP2008527351A (en) * 2005-01-06 2008-07-24 イースタン バージニア メディカル スクール Apolipoprotein A-II isoform as a biomarker for prostate cancer
EP2325306B1 (en) * 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
WO2006094704A2 (en) * 2005-03-03 2006-09-14 Chemcom S.A. Natural ligand of g protein coupled receptor rcc356 and uses thereof
KR20150031459A (en) * 2005-03-07 2015-03-24 제넨테크, 인크. Methods and Compositions for Modulating TWEAK and FN14 Activity
US8057990B2 (en) * 2005-03-08 2011-11-15 Takeda Pharmaceutical Company Limited Screening method
JPWO2006112451A1 (en) * 2005-04-18 2008-12-11 国立大学法人三重大学 Anticancer agent containing protein C inhibitor
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
CN100347307C (en) * 2005-07-25 2007-11-07 中国人民解放军第四军医大学 Recombination chimeric molecule Cb1-Grb2(SH2)-RING eukaryotic expression plasmid and antitumor genetic medicine use
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
WO2007022635A2 (en) * 2005-08-25 2007-03-01 The University Of Manitoba Methods of attenuating prostate tumor growth by insulin-like growth factor binding protein-3 (igfbp-3)
DE102005041616B4 (en) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
US20070161060A1 (en) * 2005-09-07 2007-07-12 Anderson Richard A Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
US20090270314A1 (en) * 2005-09-29 2009-10-29 Tohoku University Polypeptide having anti-angiogenic activity
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US8101173B2 (en) * 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
US20090035310A1 (en) * 2006-02-28 2009-02-05 Wayne State University Cancer treatment
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
WO2007130672A2 (en) * 2006-05-05 2007-11-15 University Of South Florida Urodilatin cancer treatment
US8309528B2 (en) * 2006-05-10 2012-11-13 The Trustees Of Columbia University In The City Of New York Two pore channels as regulators of proliferation in cancer
WO2008014404A2 (en) * 2006-07-26 2008-01-31 The University Of Chicago Receptor-mediated delivery : compositions and methods
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
KR20090064378A (en) 2006-08-10 2009-06-18 온코세라피 사이언스 가부시키가이샤 Genes and polypeptides relating breast cancers
CA2663571A1 (en) * 2006-09-13 2008-03-20 Nuvelo, Inc. Methods for treating cancer
CA2666057C (en) * 2006-10-26 2016-10-11 Genentech, Inc. Genetic variations associated with tumors
CN101595213A (en) * 2006-11-13 2009-12-02 霍夫曼-拉罗奇有限公司 The antibody of Cancerous disease modifying
US8420591B2 (en) * 2006-12-08 2013-04-16 Dana-Farber Cancer Institute, Inc. MUC1 and galectin-3
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080200387A1 (en) * 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
US7816082B2 (en) * 2007-03-06 2010-10-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of identifying pancreatic cancer cells
GB0709092D0 (en) * 2007-05-11 2007-06-20 Borrebaeck Carl Diagnosis and method of disease
ES2424976T3 (en) * 2007-06-03 2013-10-10 Oncotx, Inc. Cancer-related isoforms of components of transcription factor complexes such as biomarkers and drug targets
DK2567707T3 (en) * 2007-07-27 2017-07-31 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
US20090130105A1 (en) * 2007-08-28 2009-05-21 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
US20090123439A1 (en) * 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009077570A1 (en) * 2007-12-17 2009-06-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of fzc18-containing collagen 18 polypeptides for the treatment, diagnosis and outcome prediction of diseases
WO2009100127A2 (en) * 2008-02-05 2009-08-13 The Regents Of The University Of California Isolated brca1 peptides and method of use
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20110052494A1 (en) * 2008-07-21 2011-03-03 Tweten Rodney K H-antigen binding polypeptides and methods of use
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
EP2344544A2 (en) * 2008-09-26 2011-07-20 ProteoSys AG Novel antibodies recognizing native annexin a3
US8394924B2 (en) * 2008-10-23 2013-03-12 Massachusetts Institute Of Technology Directed engagement of activating Fc receptors
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2385114A4 (en) * 2008-12-25 2012-08-08 Univ Tokyo Diagnosis of treatment of cancer using anti-tm4sf20 antibody
AU2010232490B2 (en) * 2009-04-03 2016-08-11 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
AU2010234334B2 (en) * 2009-04-08 2014-10-09 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
SG10201401976YA (en) * 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
JP5808052B2 (en) 2009-05-29 2015-11-10 中外製薬株式会社 Pharmaceutical composition comprising antagonist of EGF family ligand as ingredient
US9241949B2 (en) * 2009-08-14 2016-01-26 Susann Brady-Kalnay Compositions and methods for treating cancer
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
WO2011094446A1 (en) 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
ES2638871T3 (en) 2010-02-04 2017-10-24 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CN106957356B (en) * 2010-05-11 2021-05-25 弗雷德哈钦森癌症研究中心 Chlorotoxin variants, conjugates, and methods of use thereof
KR101879225B1 (en) * 2010-07-15 2018-07-17 세키스이 메디칼 가부시키가이샤 Method for detecting malignant tumor cells
GB201103631D0 (en) * 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
LT2703486T (en) * 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR101972446B1 (en) * 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)-binding proteins
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед ANTIGENCY BINDING SPECIFICALLY Binds to ALL
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
RU2719132C2 (en) 2011-06-30 2020-04-17 Чугаи Сейяку Кабусики Кайся Heterodimerised polypeptide
CN102268089A (en) * 2011-07-05 2011-12-07 上海交通大学 AGR2 (Anterior Gradient-2) blocking antibody and application thereof
WO2013062083A1 (en) 2011-10-28 2013-05-02 ファーマロジカルズ・リサーチ プライベート リミテッド Cancer stem cell-specific molecule
CN104053672A (en) * 2011-11-11 2014-09-17 瑞纳神经科学公司 Antibodies specific for Trop-2 and their uses
WO2013077186A1 (en) * 2011-11-21 2013-05-30 国立大学法人筑波大学 Activity modulator, medicinal agent comprising same, use of cd300a gene-deficient mouse, and anti-cd300a antibody
CN104302324A (en) 2011-12-08 2015-01-21 生物测试股份公司 Uses of immunoconjugates targeting cd138
ITRM20120060A1 (en) * 2012-02-21 2013-08-22 Consiglio Nazionale Ricerche PEPTIDES ABLE TO RELEASE THE MDM2 / MDM4 HETERODYMER AND THEIR USE IN CANCER TREATMENT.
WO2013133253A1 (en) * 2012-03-08 2013-09-12 独立行政法人科学技術振興機構 Anticancer agent
RU2678127C2 (en) 2012-11-13 2019-01-23 Бионтех Аг Agents for treatment of claudin expressing cancer diseases
EP2928913A1 (en) 2012-12-10 2015-10-14 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AU2013370932B2 (en) * 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CN111643663A (en) 2013-03-15 2020-09-11 细胞基因公司 Modified T lymphocytes
JPWO2014208482A1 (en) * 2013-06-24 2017-02-23 中外製薬株式会社 A therapeutic agent for non-small cell lung cancer other than adenocarcinoma comprising humanized anti-Epiregulin antibody as an active ingredient
US9879081B2 (en) * 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015003114A1 (en) 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CA2931684C (en) * 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3096770A4 (en) * 2014-01-16 2017-12-06 Rowan University Modulation of cellular localization of cyclin c
WO2015138411A1 (en) * 2014-03-10 2015-09-17 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015175965A1 (en) * 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
EA034081B1 (en) 2014-07-29 2019-12-25 Селлектис Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
EP3194432B1 (en) * 2014-07-31 2019-04-10 Cellectis Ror1 specific multi-chain chimeric antigen receptor
JP7084138B2 (en) * 2014-08-19 2022-06-14 ノバルティス アーゲー Anti-CD123 Chimeric Antigen Receptor (CAR) for use in cancer treatment
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114621969A (en) * 2014-09-17 2022-06-14 诺华股份有限公司 Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6718444B2 (en) * 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） T cell receptors directed against Bob1 and uses thereof
US10047138B1 (en) * 2014-12-03 2018-08-14 Amgen Inc. Fusion protein, cells expressing the fusion protein, and uses thereof
EP3240803B1 (en) 2014-12-29 2021-11-24 Novartis AG Methods of making chimeric antigen receptor-expressing cells
AU2016216149B2 (en) * 2015-02-06 2022-03-31 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
US10195272B2 (en) * 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
SG10201912978PA (en) * 2015-07-21 2020-02-27 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
EP3378492A4 (en) * 2015-11-20 2019-11-13 Kyushu University National University Corporation Immunoregulatory agent
US11648268B2 (en) 2015-12-09 2023-05-16 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
EP3507361A1 (en) 2016-08-30 2019-07-10 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
CN109963585A (en) * 2016-09-21 2019-07-02 阿尔勒治疗公司 The fusions for treating cancer including cell-penetrating peptides, multi-epitope and TLR peptide agonists
US20200016202A1 (en) * 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
KR20190085528A (en) * 2016-11-22 2019-07-18 싱가포르국립대학교 Blocking chimeric antigen receptors and CD7 expression for immunotherapy of T-cell malignancies
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
AU2018237159A1 (en) 2017-03-22 2019-09-05 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR20200115511A (en) * 2017-12-29 2020-10-07 시티 오브 호프 Meditope-enabled T cells
EP3773912A1 (en) * 2018-04-10 2021-02-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
JP7374502B2 (en) * 2018-05-03 2023-11-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション OCA-B peptide conjugates and treatment methods
TW202138388A (en) 2019-12-30 2021-10-16 美商西根公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
CN115397461A (en) * 2020-02-05 2022-11-25 纪念斯隆-凯特琳癌症中心 Chimeric antigen receptor with CD28 mutation and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037134A (en) 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
GB9517060D0 (en) * 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives

Also Published As

Publication number Publication date
WO2002036142A2 (en) 2002-05-10
CA2427858A1 (en) 2002-05-10
WO2002036142A3 (en) 2003-02-27
US7229960B2 (en) 2007-06-12
US20030105000A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2002220265A1 (en) Compositions for inhibiting grb7
AU2001274579A1 (en) Resist composition
AU2002218266A1 (en) Novel indanylidene compounds
AU2001292518A1 (en) Novel compounds
AU1530001A (en) Inhibitor compositions
AUPQ875700A0 (en) Combination compositions
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
AU2002338709A1 (en) Workability-improving agents for cement compositions
AU2001239765A1 (en) Novel compounds
AU2001246998A1 (en) Novel compounds
AU2001241098A1 (en) Composition
AU2001253362A1 (en) Novel compounds
AU2002231077A1 (en) Novel compounds
AU2001256964A1 (en) Novel compounds
AU2001245615A1 (en) Pouched composition
AU2002232383A1 (en) Compositions for microlithography
AU2001275201A1 (en) Acne-treating composition
AU2001230689A1 (en) Novel compounds
AU2001287852A1 (en) Composition
AU2002216060A1 (en) Novel compounds
AU2001235764A1 (en) Compositions
AU2001276890A1 (en) Novel compounds
AU2001253351A1 (en) Rheology-controlled epoxy-based compositions
AU2001287732A1 (en) Copolycarbonate-based composition
AU2001262163A1 (en) Composition